Topical treatment in vitiligo and the potential uses of new drug delivery systems

Indian Journal of Dermatology, Venereology and Leprology

Volumn 76, Issue 3, 2010, Pages 231-238

  Garg, Bhawna Jain ^a   Saraswat, Abir ^b   Bhatia, Amit ^a   Katare, Om Prakash ^a  

^a PANJAB UNIVERSITY   (India)

^b Skin Clinic   (India)

Author keywords

Novel drug delivery; Phospholipid based carriers; Topical therapies; Vitiligo

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; BENZOCAINE; CALCIPOTRIOL; CARRIER PROTEIN; COLCHICINE; CORTICOSTEROID; COSMETIC; DITHRANOL; DOXORUBICIN; DRUG CARRIER; DYE; ETHOSOME; FUNGISOME GEL; LIPID EMULSION; LIPOSOME; METHOXSALEN; MINOXIDIL; MONOBENZONE; ORGANOGEL; PHOSPHATIDYLCHOLINE; PHOSPHOLIPID; PHYCOCYANIN; PIMECROLIMUS; POLYMER; PSORALEN DERIVATIVE; PSORISOME; SOLID LIPID NANOPARTICLE; TACALCITOL; TACROLIMUS; TRANSFEROSOME; TRIOXYSALEN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATROPHY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; GEL; HUMAN; HYPERCALCEMIA; HYPERTRICHOSIS; HYPOPIGMENTATION; PHOTOCHEMOTHERAPY; PHOTOTHERAPY; REVIEW; SKIN IRRITATION; ULTRAVIOLET A RADIATION; VITILIGO;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; ANIMALS; DRUG DELIVERY SYSTEMS; HUMANS; OINTMENTS; VITILIGO;

EID: 77952649636     PISSN: 03786323     EISSN: 09733922     Source Type: Journal    
DOI: 10.4103/0378-6323.62961     Document Type: Review

References (54)

1. Nogueira LS, Zancanaro PC, Azambuja RD. Vitiligo and emotions. An Bras Dermatol 2009;84:41-5.
2. Sehgal VN, Srivastava G. Vitiligo: Compendium of clinicoepidemiological features. Indian J Dermatol Venereol Leprol 2007;73:149-56.
3. st ed. Mumbai: Fulford India Ltd; 2000. p. 18-22.
4. Song MS, Hann SK, Ahn PS, Im S, Park YK. Clinical study of vitiligo:Comparative study of type A and B vitiligo. Ann Dermatol 1994;6:22-30.
5. Njoo MD, Westerhof W. Vitiligo: Pathogenesis and treatment. Am J Clin Dermatol 2001;2:167-81.
6. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Guideline forthe diagnosis and management of vitiligo. Br J Dermatol 2008;159:1051-76.
7. Lotti T, Gori A, Zanieri F, Colucci R, Moretti S. Vitiligo: New and emerging treatments. Dermatol Ther 2008;21:110-7.
8. Ference JD, Last AR. Choosing topical corticosteroids. Am Fam Physician 2009;79:135-40.
9. Sanclemente G, Garcia JJ, Zuleta JJ, Diehl C, Correa C, Falabella R. A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. J Eur Acad Dermatol Venereol 2008;22:1359-64.
10. Godse KV. Comparison of two diluents of 1% methoxsalen in the treatment of vitiligo. Indian J Dermatol Venereol Leprol 2008;74:298-9.
11. Köster W, Wiskemann A. Phototherapy with UV-B in vitiligo. Z Hautkr 1990;65:1022-4.
12. Percivalle S, Piccino R, Caccialanza M, Forti S. Narrowband UVB phototherapy in vitiligo: Evaluation of results in 53 patients. G Ital Dermatol Venereol 2008;143:9-14.
13. Abdulla SJ, Desgroseilliers JP. Treatment of vitiligo with narrowband ultraviolet B: Advantages and disadvantages. J Cutan Med Surg 2008;12:174-9.
14. Rodríguez-Martín M, García Bustínduy M, Sáez Rodríguez M, Noda Cabrera A. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. Br J Dermatol 2009;160:409-14.
15. Birlea SA, Costin GE, Norris DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. Med Res Rev 2009;29:514-46.
16. Dusso AS, Brown AJ. Mechanism of vitamin D action and its regulation. Am J Kidney Dis 1998;32: S13-24.
17. Boone B, Ongenae K, Van Geel N, Vernijns S, De Keyser S, Naeyaert JM. Topical pimecrolimus in the treatment of vitiligo. Eur J Dermatol 2007;17:55-61.
18. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002;47:789-91.
19. Bentley MV, Vianna RF, Wilson S, Collett JH. Characterization of the influence of some cyclodextrins on the stratum corneum from the hairless mouse. J Pharm Pharmacol 1997;49:397-402.
20. Farajzadeh S, Daraei Z, Esfandiarpour I, Hosseini SH. The efficacy of pimecrolimus 1% cream combined with microdermabrasion in the treatment of nonsegmental childhood vitiligo: A randomized placebo-controlled study. Pediatr Dermatol 2009;26:286-91.
21. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998;38:647-68.
22. Njoo MD, Vodegel RM, Westerhof W. Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. J Am Acad Dermatol 2000;42:760-9.
23. Tanioka M, Miyachi Y. Camouflage for vitiligo. Dermatol Ther 2009;22:90-3.
24. Hsu S. Camouflaging vitiligo with dihydroxyacetone. Dermatol Online J 2008;14:23.
25. Rajatanavin N, Suwanachote S, Kulkollakarn S. Dihydroxyacetone: A safe camouflaging option in vitiligo. Int J Dermatol 2008;47:402-6.
26. Idson B. Topical drug delivery: Needs, theory and practice. Pharm Tech 1981;70:74-5.
27. Hadgraft J. Modulation of the barrier function of the skin. Skin Pharmacol Appl Skin Physiol 2001;14:72-81.
28. Roberts MS. Targeted drug delivery to the skin and deeper tissues: Role of physiology, solute structure and disease. Clin Exp Pharmacol Physiol 1997;24:874-9.
29. Kar PK, Snehi PS, Jha PK. Treatment of vitiligo with psoralen. Indian J Dermatol Venereol Leprol 1990;56:121-2.
30. Handa S, Pandhi R, Kaur I. Vitiligo: A retrospective comparative analysis of treatment modalities in 500 patients. J Dermatol 2001;28:461-6.
31. Cross SE, Roberts MS. Physical enhancement of transdermal drug application: Is delivery technology keeping up with pharmaceutical development? Curr Drug Deliv 2004;1:81-92.
32. Date AA, Naik B, Nagarsenker MS. Novel drug delivery systems: Potential in improving topical delivery of antiacne agents. Skin Pharmacol Physiol 2006;19:2-16.
33. Westesen K. Novel lipid-based colloidal dispersions as potential drug administration systems - expectations and reality. Colloid Polym Sci 2000;278:608-18.
34. Cevc G. Lipid vesicles and other colloids as drug carriers on the skin. Adv Drug Deliv Rev 2004;56:675-711.
35. Valenta C, Wanka M, Heidlas J. Evaluation of novel soyalecithin formulations for dermal use containing ketoprofen as a model drug. J Control Release 2000;63:165-73.
36. Safra T, Muggia F, Jeffers S, Tsao-Wei DD, Groshen S, Lyass O, et al. Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2. Ann Oncol 2000;11:1029-33.
37. Sinico C, Valenti D, Manconi M, Lai F, Fadda AM. Cutaneous delivery of 8-methoxypsoralen from liposomal and niosomal carriers. J Drug Deliv Sci Technol 2006;16:115-20.
38. Saraswat A, Agarwal R, Katare OP, Kaur I, Kumar B. A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis. J Dermatolog Treat 2007;18:40-5.
39. Manconia M, Pendás J, Ledón N, Moreira T, Sinico C, Saso L, et al. Phycocyanin liposomes for topical anti-inflammatory activity: In-vitro in-vivo studies. J Pharm Pharmacol 2009;61:423-30.
40. Jain B, Singh B, Katare OP, Vyas SP. Development and characterization of minoxidil-loaded liposomal system for delivery to pilosebaceous units. J Liposome Res 2009 in press.
41. Singh HP, Utreja P, Tiwary AK, Jain S. Elastic liposomal formulation for sustained delivery of colchicine: In vitro characterization and in vivo evaluation of anti-gout activity. AAPS J 2009;11:54-64.
42. Cevc G, Blume G. Hydrocortisone and dexamethasone in very deformable drug carriers have increased biological potency, prolonged effect, and reduced therapeutic dosage. Biochim Biophys Acta 2004;1663:61-73.
43. Fesq H, Lehmann J, Kontny A, Erdmann I, Theiling K, Rother M, et al. Improved risk-benefit ratio for topical triamcinolone acetonide in transfersome in comparison with equipotent cream and ointment: A randomized controlled trial. Br J Dermatol 2003;149:11-9.
44. Fang YP, Tsai YH, Wu PC, Huang YB. Comparison of 5-aminolevulinic acid-encapsulated liposome versus ethosome for skin delivery for photodynamic therapy. Int J Pharm 2008;356:144-52.
45. Rao Y, Zheng F, Zhang X, Gao J, Liang W. In vitro percutaneous permeation and skin accumulation of finasteride using vesicular ethosomal carriers. AAPS PharmSciTech 2008;9:860-5.
46. Maestrelli F, Capasso G, Gonzalez-Rodriguez ML, Rabasco AM, Ghelardini C, Mura P. Effect of preparation technique on the properties and in vivo efficacy of benzocaine-loaded ethosomes. J Liposome Res 2009;4:1-8.
47. Changez M, Varshney M, Chander J, Dinda AK. Effect of the composition of lecithin/n-propanol/isopropyl myristate/water microemulsions on barrier properties of mice skin for transdermal permeation of tetracaine hydrochloride: In vitro. Colloids Surf B Biointerfaces 2006;50:18-25.
48. Fang JY, Leu YL, Chang CC, Lin CH, Tsai YH. Lipid nano/submicron emulsions as vehicles for topical flurbiprofen delivery. Drug Deliv 2004;11:97-105.
49. Chen H, Chang X, Weng T, Zhao X, Gao Z, Yang Y, et al. A study of microemulsion systems for transdermal delivery of triptolide. J Control Release 2004;98:427-36.
50. Liu H, Wang Y, Han F, Yao H, Li S. Gelatin-stabilised microemulsion-based organogels facilitates percutaneous penetration of cyclosporin A in vitro and dermal pharmacokinetics in vivo. J Pharm Sci 2007;96:3000-9.
51. Shaikh IM, Jadhav KR, Gide PS, Kadam VJ, Pisal SS. Topical delivery of aceclofenac from lecithin organogels: Preformulation study. Curr Drug Deliv 2006;3:417-27.
52. Bhalekar MR, Pokharkar V, Madgulkar A, Patil N, Patil N. Preparation and evaluation of miconazole nitrate-loaded solid lipid nanoparticles for topical delivery. AAPS PharmSciTech 2009;10:289-96.
53. Chen H, Chang X, Du D, Liu W, Liu J, Weng T, et al. Podophyllotoxin- loaded solid lipid nanoparticles for epidermal targeting. J Control Release 2006;110:296-306.
54. Fang JY, Fang CL, Liu CH, Su YH. Lipid nanoparticles as vehicles for topical psoralen delivery: Solid lipid nanoparticles (SLN) versus nanostructured lipid carriers (NLC). Eur J Pharm Biopharm 2008;70:633-40.